The company was born in the laboratory, as part of the R&D department of Sequentia Biotech. Led by Dr. Luis Matías Hernández, it was set up to research and optimize different plants that produce various medicinal and aromatic compounds in their trichomes, starting with Artemisia annua. Continuing the positive results obtained in laboratory and field studies, in October 2018, Biotech Tricopharming Research was founded with the aim of continuing the development and commercialization of the enhanced Artemisia annua, known as Artennua.
In parallel, the company is applying its technology to other medicinal and aromatic plants, such as lavender, thyme, mint, and basil, among others. In addition to continuing with its R&D development, Biotech Tricopharming Research also offers customized R&D services and field trials to other companies and research centers interested in improving the commercial production of plants for the pharmaceutical, nutraceutical, and cosmetic sectors.
• General Characteristics
- ACTIVITY: Biotechnology to enhance the therapeutic potential of various medicinal plants.
- LOCATION: Barcelona.
- DATE OF FOUNDATION: 10/2018.
- CATEGORY: small agropharma/plant biotechnology company.
- CONTACT: (+34) 695 124 590.
• Business Structure
- NUMBER OF EMPLOYEES: 5.
- INCOME: –
- GENERAL DESCRIPTION: Biotech Tricopharming Research SL is a biotechnology startup founded in 2018 after several years of R&D. Our general mission is to create the know-how and technologies necessary to enhance the therapeutic potential of various medicinal and aromatic plants (MAPs). The Biopharmaceutical Agriculture or Biopharming combines biotechnology and agriculture to produce valuable pharmaceutical products in plants but at a reduced cost. In our first product, Artennua®, we increase the production of various compounds of interest in the plant Artemisia annua; a plant used to combat malaria, cancer, as well as other diseases in both humans and animals.
- BUSINESS LINES: Sale of Artennua® for the nutraceutical, natural cosmetics, and animal health sectors. License for the use of our technology TricoStimulant™ for different MAP plants.
- INFRASTRUCTURE: Head office in Barcelona. Operational, production, and experimental headquarters in Tenerife.
- INTERESTING DATA: Although created in 2018, the R&D was developed in the company Sequentia Biotech SL from 2015 to 2018.
• R&D Activities/Interests
TECHNOLOGICAL OFFER/DEMAND:
- We offer consulting and custom R&D projects to companies or research centers to enhance the therapeutic potential of various MAPs.
- We develop custom bio-stimulants .
- We seek collaborations with other companies and/or research centers for new R&D projects.
- We seek collaborations with other companies and/or research centers to study stability and new formats for different bio-stimulants.
• Participation in projects
PROJECTS IN DEVELOPMENT
- Platform for the production of therapeutic molecules in plants. CDTI.
COMPLETED PROJECTS
- Biotechnology for production of the molecule artemisinin in the trichomes of the plant Artemisia annua. Validation of the technology TricoStimulant™ in the field. MINECO-CDTI.